Panel of Five Serum Biomarkers Identifies COVID-19 Patients at High Risk to Develop Serious Complications
By LabMedica International staff writers Posted on 18 Aug 2020 |

Transmission electron microscope image of SARS-CoV-2 (2019-nCoV), the virus that causes COVID-19, isolated from a patient in the U.S.A. Virus particles are shown emerging from the surface of cells cultured in the laboratory. (Image courtesy of National Institute of Allergy and Infectious Diseases via Wikimedia Commons)
A recent paper suggested that elevated levels of five serum biomarkers could be used to identify COVID-19 patients who are at high risk for serious complications or death.
Based on early Chinese COVID-19 studies showing that certain biomarkers were associated with bad outcomes, investigators at George Washington University (Washington, DC, USA) determined levels of five serum biomarkers in samples obtained from 299 patients diagnosed with COVID-19 admitted to George Washington Hospital between March 12 and May 9, 2020.
The five biomarkers measured were:
1) D-dimer, a fibrin degradation product present in the blood after a blood clot has been degraded by fibrinolysis. It was so named because it contains two D fragments of the fibrin protein joined by a cross-link. D-dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in patients with suspected thrombotic disorders. A four-fold increase in the protein is a strong indicator of mortality in those suffering from COVID-19.
2) C-reactive protein (CRP) is a ring-shaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T-cells.
3) IL-6 (interleukin-6) is an important mediator of fever and of the acute phase response. There is some early evidence that IL-6 can be used as an inflammatory marker for severe COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic.
4). Lactate dehydrogenase (LDH) is an enzyme found in nearly all living cells. LDH catalyzes the conversion of lactate to pyruvate and back, as it converts NAD+ to NADH and back. LDH is expressed extensively in body tissues, such as blood cells and heart muscle. Since it is released during tissue damage, LDH is a marker of common injuries and disease such as heart failure.
5) Ferritin is a universal intracellular protein that stores iron and releases it in a controlled fashion. Plasma ferritin is an indirect marker of the total amount of iron stored in the body and is used as a diagnostic test for iron-deficiency anemia.
For each patient, age, sex, BMI, comorbidities, and medications were recorded. Laboratory tests were performed either in the emergency room prior to admission or after the admission orders, and patients were placed in one of the special COVID-19 units. In addition to routine admission laboratory studies, CRP, D-dimer, IL-6, ferritin, and LDH were recorded. Further, the maximum oxygen requirements prior to transfer to ICU, transfer to the ICU, necessity for mechanical ventilation, and discharge status were noted.
Results revealed that elevated levels of these biomarkers were associated with inflammation and bleeding disorder, showing an independent increased risk for ICU admission, invasive ventilatory support, and death. The highest odds of death occurred when the LDH level was greater than 1200 units/liter and a D-dimer level was greater than 3 microgram/milliliter.
"When we first started treating COVID-19 patients, we watched them get better or get worse, but we did not know why," said contributing authour Dr. Juan Reyes, assistant professor of medicine at the George Washington University. "Some initial studies had come out of China showing certain biomarkers were associated with bad outcomes. There was a desire to see if that was true for our patients here in the U.S."
"We hope these biomarkers help physicians determine how aggressively they need to treat patients, whether a patient should be discharged, and how to monitor patients who are going home, among other clinical decisions," said first author Dr. Shant Ayanian, assistant professor of medicine at George Washington University.
The study was published in the July 17, 2020, online edition of the journal Future Medicine.
Related Links:
George Washington University
Based on early Chinese COVID-19 studies showing that certain biomarkers were associated with bad outcomes, investigators at George Washington University (Washington, DC, USA) determined levels of five serum biomarkers in samples obtained from 299 patients diagnosed with COVID-19 admitted to George Washington Hospital between March 12 and May 9, 2020.
The five biomarkers measured were:
1) D-dimer, a fibrin degradation product present in the blood after a blood clot has been degraded by fibrinolysis. It was so named because it contains two D fragments of the fibrin protein joined by a cross-link. D-dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in patients with suspected thrombotic disorders. A four-fold increase in the protein is a strong indicator of mortality in those suffering from COVID-19.
2) C-reactive protein (CRP) is a ring-shaped, pentameric protein found in blood plasma, whose circulating concentrations rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T-cells.
3) IL-6 (interleukin-6) is an important mediator of fever and of the acute phase response. There is some early evidence that IL-6 can be used as an inflammatory marker for severe COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic.
4). Lactate dehydrogenase (LDH) is an enzyme found in nearly all living cells. LDH catalyzes the conversion of lactate to pyruvate and back, as it converts NAD+ to NADH and back. LDH is expressed extensively in body tissues, such as blood cells and heart muscle. Since it is released during tissue damage, LDH is a marker of common injuries and disease such as heart failure.
5) Ferritin is a universal intracellular protein that stores iron and releases it in a controlled fashion. Plasma ferritin is an indirect marker of the total amount of iron stored in the body and is used as a diagnostic test for iron-deficiency anemia.
For each patient, age, sex, BMI, comorbidities, and medications were recorded. Laboratory tests were performed either in the emergency room prior to admission or after the admission orders, and patients were placed in one of the special COVID-19 units. In addition to routine admission laboratory studies, CRP, D-dimer, IL-6, ferritin, and LDH were recorded. Further, the maximum oxygen requirements prior to transfer to ICU, transfer to the ICU, necessity for mechanical ventilation, and discharge status were noted.
Results revealed that elevated levels of these biomarkers were associated with inflammation and bleeding disorder, showing an independent increased risk for ICU admission, invasive ventilatory support, and death. The highest odds of death occurred when the LDH level was greater than 1200 units/liter and a D-dimer level was greater than 3 microgram/milliliter.
"When we first started treating COVID-19 patients, we watched them get better or get worse, but we did not know why," said contributing authour Dr. Juan Reyes, assistant professor of medicine at the George Washington University. "Some initial studies had come out of China showing certain biomarkers were associated with bad outcomes. There was a desire to see if that was true for our patients here in the U.S."
"We hope these biomarkers help physicians determine how aggressively they need to treat patients, whether a patient should be discharged, and how to monitor patients who are going home, among other clinical decisions," said first author Dr. Shant Ayanian, assistant professor of medicine at George Washington University.
The study was published in the July 17, 2020, online edition of the journal Future Medicine.
Related Links:
George Washington University
Latest Molecular Diagnostics News
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
- Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
- Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
- Simple Urine Test Could Help Patients Avoid Invasive Scans for Kidney Cancer
- New Bowel Cancer Blood Test to Improve Early Detection
- Refined Test Improves Parkinson’s Disease Diagnosis
- New Method Rapidly Diagnoses CVD Risk Via Molecular Blood Screening
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more